Development of
mRNA Universal Coronavirus Vaccine

by NORVAX UK, mRNA UCV Consortium, Vaxcomm, Norsk Vaksinefabrikk

Our Goal

The goal of the mRNA Universal Coronavirus Vaccine (mRNA UCV) in development by Norvax UK (ECAM Vaccines Limited) with Norsk Vaksinefabrikk (Norvax AS) and the mRNA UCV Consortium is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support innovation for future pandemic preparedness.

With development of the mRNA Vaccine Platform in cooperation with SINTEF and strategic technology vendors, scientists at mRNA UCV Consortium, ECAM Vaccines and Norsk Vaksinefabrikk will program multiple mRNA targets on the virus for delivery of a Universal Coronavirus Vaccine for SARS-CoV-2 Variants of Concern (VOC) including Alpha, Beta, Gamma, Delta VOCs, and expected future SARS-CoV-2 VOCs.

The mRNA Vaccine Platform

Starting with the mRNA UCV flagship product development, Norvax UK, Norsk Vaksinefabrikk, mRNA UCV Consortium, and members of Vaxcomm – The Vaccine Commons, are openly supported to apply the mRNA Vaccine Platform to develop novel mRNA vaccines
for infectious disease, therapeutics and cancers.

Learn More

Members of the mRNA UCV Consortium, and VaxComm – The Vaccine Commons, are openly supported to apply the mRNA Vaccine Platform by Norvax to develop safe and effective novel mRNA vaccines for infectious diseases, therapeutics and cancers.

LEARN MORE